乳腺癌同侧复发保乳术后三维适形部分乳腺再照射的NRG/RTOG 1014 II期试验
NRG Oncology/RTOG 1014是一项II期单臂前瞻性试验,评估同侧乳腺复发患者二次保乳术后行三维适形部分乳腺再照射(45 Gy/30次/15天)的疗效与不良反应。58例可评估患者中,5年同侧乳腺复发累积发生率为5%,同侧乳房切除累积发生率为10%,无远处转移生存率和总生存率均为95%,仅4例(7%)出现3级晚期不良事件。结论提示该方案可作为乳房切除术的有效替代。
要点
- 二次保乳术后部分乳腺再照射的5年同侧复发率为5%。
- 5年同侧乳房切除累积发生率为10%,90%患者保留乳房。
- 3级晚期不良事件仅7%,无4级及以上事件。
核心结论
- 对于保乳加全乳放疗后同侧乳腺复发患者,二次保乳联合辅助部分乳腺再照射可实现90%的保乳率,且同侧再复发风险低。
- 该治疗方式可能是乳房切除术的有效替代选择。
研究设计与样本
- NRG Oncology/RTOG 1014为II期单臂前瞻性临床试验,2010年6月4日开放,2013年6月18日关闭,中位随访5.5年。
- 入组标准为保乳加全乳放疗后超过1年出现同侧单灶复发、肿瘤小于3 cm且切除边缘阴性。
- 共65例女性入组,58例可评估分析,平均年龄65.12岁(SD 9.95),48例(83%)为白人。
主要发现
- 58例中复发肿瘤23例(40%)为非浸润性,35例(60%)为浸润性;53例(91%)肿瘤≤2 cm,所有肿瘤临床淋巴结阴性。
- 44例(76%)雌激素受体阳性,33例(57%)孕激素受体阳性,10例(17%)ERBB2过表达。
- 4例出现同侧乳腺复发,5年累积发生率为5%(95%CI 1%-13%)。
- 7例接受同侧乳房切除术,5年累积发生率为10%(95%CI 4%-20%)。
- 无远处转移生存率和总生存率均为95%(95%CI 85%-98%)。
关键数值与推荐
- 再照射方案为三维适形部分乳腺照射,1.5 Gy每日两次,共30次,15天完成,总剂量45 Gy。
临床怎么用
- 对于保乳加全乳放疗后同侧单灶复发(肿瘤<3 cm、切缘阴性、距初次治疗>1年)患者,可考虑二次保乳联合部分乳腺再照射以替代乳房切除术。
- 治疗前应评估肿瘤大小、灶数、切缘及复发间隔时间是否符合入组条件。
局限性
- 本研究为II期单臂试验,样本量有限(58例可评估),缺乏随机对照比较。
- 中位随访5.5年,长期疗效与晚期毒性需进一步随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mastectomy is standard for recurrence of breast cancer after breast conservation therapy with whole breast irradiation. The emergence of partial breast irradiation led to consideration of its application for reirradiation after a second lumpectomy for treatment of recurrence of breast cancer in the ipsilateral breast. OBJECTIVES: To assess the effectiveness and adverse effects of partial breast reirradiation after a second lumpectomy and whether the treatment is an acceptable alternative to mastectomy. DESIGN, SETTING, AND PARTICIPANTS: The NRG Oncology/Radiation Therapy Oncology Group 1014 trial is a phase 2, single-arm, prospective clinical trial of 3-dimensional, conformal, external beam partial breast reirradiation after a second lumpectomy for recurrence of breast cancer in the ipsilateral breast after previous whole breast irradiation. The study opened on June 4, 2010, and closed June 18, 2013. Median follow-up was 5.5 years. This analysis used all data received at NRG Oncology through November 18, 2018. Eligible patients experienced a recurrence of breast tumor that was less than 3 cm and unifocal in the ipsilateral breast more than 1 year after breast-conserving therapy with whole breast irradiation and who had undergone excision with negative margins. INTERVENTIONS: Adjuvant partial breast reirradiation, 1.5 Gy twice daily for 30 treatments during 15 days (45 Gy), using a 3-dimensional conformal technique. MAIN OUTCOMES AND MEASURES: The main outcomes of the present study were the predefined secondary study objectives of recurrence of breast cancer in the ipsilateral breast, late adverse events (>1 year after treatment), mastectomy incidence, distant metastasis-free survival, overall survival, and circulating tumor cell incidence. RESULTS: A total of 65 women were enrolled, with 58 evaluable for analysis (mean [SD] age, 65.12 [9.95] years; 48 [83%] white). Of the recurrences of breast cancer in the ipsilateral breast, 23 (40%) were noninvasive and 35 (60%) were invasive. In all 58 patients, 53 (91%) had tumors 2 cm or smaller. All tumors were clinically node negative. A total of 44 patients (76%) tested positive for estrogen receptor, 33 (57%) for progesterone receptor, and 10 (17%) for ERBB2 (formerly HER2 or HER2/neu) overexpression. Four patients had breast cancer recurrence, with a 5-year cumulative incidence of 5% (95% CI, 1%-13%). Seven patients underwent ipsilateral mastectomies for a 5-year cumulative incidence of 10% (95% CI, 4%-20%). Both distant metastasis-free survival and overall survival rates were 95% (95% CI, 85%-98%). Four patients (7%) had grade 3 and none had grade 4 or higher late treatment adverse events. CONCLUSIONS AND RELEVANCE: For patients experiencing recurrence of breast cancer in the ipsilateral breast after lumpectomy and whole breast irradiation, a second breast conservation was achievable in 90%, with a low risk of re-recurrence of cancer in the ipsilateral breast using adjuvant partial breast reirradiation. This finding suggests that this treatment approach is an effective alternative to mastectomy.
引用
- Arthur DW, Winter KA, Kuerer HM, et al. Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial. JAMA Oncol. 2020. PMID: 31750868. doi:10.1001/jamaoncol.2019.4320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。